Related Experiment Video

Updated: Apr 27, 2026

Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

6.5K

Clinical implication of SGLT2 inhibitors in type 2 diabetes

Go Woon Kim1, Sung Hyun Chung

  • 1Department of Pharmacology and Clinical Pharmacy, College of Pharmacy, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul, 130-701, Republic of Korea.

Archives of Pharmacal Research
|June 22, 2014
PubMed

Insights

New SGLT2 inhibitors offer improved type 2 diabetes treatment by increasing urinary glucose excretion. These medications provide an alternative for patients not meeting glycemic targets, with a focus on efficacy and safety data.

Area of Science:

  • Endocrinology
  • Nephrology
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) treatment faces challenges in achieving glycemic targets.
  • Existing anti-diabetic agents often have side effects like hypoglycemia and weight gain.
  • Increased renal glucose reabsorption in T2DM highlights the kidney as a therapeutic target.

Purpose of the Study:

  • To review the efficacy and safety of SGLT2 inhibitors for T2DM.
  • To discuss the therapeutic potential of targeting renal glucose reabsorption.
  • To examine the clinical data and future perspectives of SGLT2 inhibitors.

Main Methods:

  • Review of clinical trial data for approved SGLT2 inhibitors.
  • Analysis of efficacy and safety profiles.
  • Examination of ongoing phase III clinical trials.

Main Results:

  • SGLT2 inhibitors reduce hyperglycemia by increasing urinary glucose excretion.
  • Approved SGLT2 inhibitors include canagliflozin, dapagliflozin, ipragliflozin, and luseogliflozin.
  • Clinical trials provide key efficacy and safety data for this drug class.

Conclusions:

  • SGLT2 inhibitors represent a novel class of oral anti-diabetic agents.
  • They offer an insulin-independent mechanism for glycemic control.
  • Further research and clinical trials are exploring their role in T2DM management.

More Related Videos

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

70.0K

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.9K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
990
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
949
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
15.2K
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
23